| HOME >> BIOLOGY >> TECHNOLOGY |
OPERATING EXPENSES:
Cost of diagnostics sold -- 50 38 69
Cost of services 28 29 90 298
Research and development:
Non-cash compensation 735 1,378 2,908 6,206
Other research and
development 15,967 14,950 49,098 39,635
Total research and
development 16,702 16,328 52,006 45,841
Selling, general and
administrative:
Non-cash compensation 1,780 1,481 5,193 7,839
Other selling, general and
administrative 2,087 2,041 7,276 6,546
Total selling, general and
administrative 3,867 3,522 12,469 14,385
TOTAL OPERATING EXPENSES 20,597 19,929 64,603 60,593
OPERATING LOSS (20,545) (19,855) (64,459) (60,160)
OTHER INCOME:
Interest and other
income, net 1,017 1,862 3,658 4,743
NET LOSS $(19,528) $(17,993) $(60,801) $(55,417)
NET LOSS PER COMMON
SHARE
Basic and diluted $(0.45) $(0.42) $(1.40) $(1.34)
SHARES USED IN COMPUTING
NET LOSS PER COMMON
SHARE
Basic and diluted 43,619,523 43,177,962 43,561,160 41,474,449
Balance Sheet Information:
September 30, 2007 December 31, 2006*
(unaudited)
Cash, cash equivalents,
interest receivable and
investment securities $ 70,736 $ 125,610
License receivable 12,000 --
Total assets 99,021
'/>"/>
| SOURCE Keryx Biopharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |